Category: Joint ventures/collaborations
-
Quest, Sloan Kettering Partner on Solid Tumor Diagnostics
2 June 2014. Quest Diagnostics in Madison, New Jersey and Memorial Sloan Kettering Cancer Center in New York are developing tests to give physicians more precise data on genetic causes of solid tumor cancers, such as breast, prostate, colon, and lung cancer. Financial and intellectual property aspects of the collaboration were not disclosed. In the…
-
Epigenetics Biotech Secures $12.9 Million Early Financing
30 May 2014. Rodin Therapeutics Inc., a biotechnology company in Boston developing therapies based on epigenetics — inherited changes in genetic activity outside of DNA — raised $12.9 million in its first venture funding round. The company is a joint venture of Proteros biostructures GmbH in Munich and Atlas Ventures in Cambridge, Massachusetts. Rodin Therapeutics…
-
Ohio State, Cancer Center Partner on Research Database
28 May 2014. Moffitt Cancer Center in Tampa and Ohio State University’s Comprehensive Cancer Center in Columbus are launching a repository of patient data and tumor samples to speed development of therapies and better match patients to clinical trials. Financial details of the Oncology Research Information Exchange Network or Orien created by the collaboration were…
-
Medical Centers to Develop Brain Signal Tracking, Therapies
28 May 2014. Massachusetts General Hospital in Boston and University of California in San Francisco are developing technologies to analyze brain activity and deliver near real-time neural stimulation therapies. The five-year project is funded by grants from Defense Advanced Research Projects Agency (DARPA) of $30 million and $26 million respectively to Mass. General and UC-San…
-
Five Pharma Companies to Share Clinical Researcher Data
27 May 2014. Five pharmaceutical companies are joining together to share their files on researchers conducting clinical trials, to speed the administrative process of starting up new studies. The Investigator Databank is a joint project of Novartis, Janssen (a division of Johnson & Johnson), Merck, Eli Lilly and Co., and Pfizer, and administered by DrugDev,…
-
Industrial Scale Graphene Production Process Devised
23 May 2014. Engineers at University of Michigan, Massachusetts Institute of Technology, and glass manufacturer Guardian Industries developed a process for producing graphene that overcomes many of the obstacles preventing industrial-scale production of this material. The findings of a research team led by MIT’s John Hart and Guardian’s Vijayen Veerasamy appear online today in the…
-
Pfizer, Biotech to Partner on Brown Fat Cell Research
22 May 2014. BioRestorative Therapies Inc. in Jupiter, Florida and the pharmaceutical company Pfizer Inc. in New York are conducting a joint study of human brown fat tissue and cell lines, to discover more about their use as a platform for therapies for type 2 diabetes and obesity. Financial and intellectual property aspects of the…
-
Partnership to Test Genome-Driven Breast Cancer Therapies
15 May 2014. Researchers at Indiana University’s medical school in Indianapolis and Paradigm, a genomic sequencing company in Ann Arbor, Michigan are enrolling patients in a clinical study testing the ability of genomic sequencing to find optimal treatments for an aggressive type of breast cancer. The study covers women with triple-negative breast cancer, a form…
-
Biopharm Starts Genetic Heart Disease Clinical Database
14 May 2014. MyoKardia Inc., a biopharmaceutical company in South San Francisco, California, began a repository of clinical data on patients with genetic heart disorders. The database, known as Sarcomeric Human Cardiomyopathy Registry, or SHaRe, is a joint project with seven medical centers specializing in these conditions in the U.S., U.K., Netherlands, and Italy. SHaRe aims…
-
Biopharm, University Partner on Universal Flu Vaccine
8 May 2014. Etubics Corp. in Seattle and University of Texas Medical Branch in Galveston are developing a new type of flu vaccine that aims to provide continuous protection against a variety of seasonal virus strains. The five-year project is funded by a $4.4 million grant from National Institute of Allergy and Infectious Diseases (NIAID),…